HLscience Co., Ltd. (KOSDAQ:239610)
South Korea · Delayed Price · Currency is KRW 8,190.00
+40.00 (0.49%)
At close: Feb 13, 2026
HLscience Revenue
HLscience had revenue of 3.45B KRW in the quarter ending September 30, 2025, a decrease of -1.22%. This brings the company's revenue in the last twelve months to 18.10B, down -8.10% year-over-year. In the year 2024, HLscience had annual revenue of 17.66B, down -30.97%.
Revenue (ttm)
18.10B
Revenue Growth
-8.10%
P/S Ratio
2.30
Revenue / Employee
212.93M
Employees
85
Market Cap
41.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17.66B | -7.92B | -30.97% |
| Dec 31, 2023 | 25.59B | -27.17B | -51.50% |
| Dec 31, 2022 | 52.76B | -51.62B | -49.45% |
| Dec 31, 2021 | 104.38B | -38.66B | -27.03% |
| Dec 31, 2020 | 143.04B | 119.33B | 503.39% |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Korea Arlico Pharm | 205.21B |
| RP Bio | 134.21B |
| Jin Yang Pharmaceutical | 117.19B |
| GeneBioTech Co. ,Ltd | 92.28B |
| Korean Drug | 62.21B |
| ChoA Pharmaceutical Co., LTD. | 60.50B |
| Kyung Nam Pharm | 56.18B |
| Seoul Pharma | 52.43B |